Zucero is an Australian-based biotechnology company focussed on the development of pixatimod, an immunotherapy for the treatment of cancer.
Pixatimod successfully completed safety evaluation in a Phase 1a clinical trial. It is currently under investigation in a Phase 1b study in combination with Opdivo® (immune checkpoint inhibitor) for pancreatic cancer, and new investigations in colon cancer is now being planned.
Company Details
- Founded
- 2016
- Address
- 1 Westlink Court, Suite 1.11,level 1,australia
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- zucero.com.au
- Keywords
- biotech, immunotherapy, pharmaceutical.
- HQ
- Darra, Queensland
Zucero Therapeutics Ltd Questions
Zucero Therapeutics Ltd's website is zucero.com.au
Zucero Therapeutics Ltd's LinkedIn profile is https://au.linkedin.com/company/zucero
Zucero Therapeutics Ltd's industry is
Biotechnology Research
Zucero Therapeutics Ltd's top competitors are
De Groot Technical Services,
Catalyst Therapeutics,
Synthesis Research,
Cre Respond,
Targagenix,
Genome Illustration,
Inia Health / Mindcheck,
Liquid Biopsy,
Bioessence Consultancy Services,
Funky Fungus.
Zucero Therapeutics Ltd's categories are Biotechnology Research
Zucero Therapeutics Ltd's founding year is 2016
